Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17094030 | 1.00 | HTT (0.33) | HTTCYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15413470 | 0.85 | CYP3A4 (0.34) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL17094302 | 0.84 | CYP3A4 (0.33) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL17094299 | 0.84 | CYP3A4 (0.33) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL262043 | 0.84 | MEN1 (0.36) | HTTCYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17093707 | 0.83 | CYP3A4 (0.33) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL17093704 | 0.83 | CYP3A4 (0.33) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL15413353 | 0.83 | HTT (0.35) | HTTCYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19285811 | 0.82 | HTT (0.32) | HTTCYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17093891 | 0.81 | HTT (0.32) | HTTCYP3A4SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | HTT 4722/4885CYP3A4 379/4885SMN1; SMN2 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.